Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase 3, Open-Label, Multicenter Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease (CAD)
Flurpiridaz (18F) for PET Assessment of Myocardial Perfusion in Patients Of Suspected Coronary Artery Disease (CAD)
Sponsor:GE Healthcare
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR8795
U.S. Government ID:NCT03354273
Contact: Kate Dalton: 347-514-3366 / keb2114@cumc.columbia.edu
Additional Study Information:

Phase 3 open-label, multicenter Study of Flurpiridaz Injection for PET Imaging for assessment of Myocardial perfusion in patients referred for Invasive Coronary Angiography because of suspected Coronary Artery Disease

Do You Qualify?
Are you at least 18 years old?YesNo
Submit
Cancel
Investigator
Andrew Einstein, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Kate Dalton
Email: keb2114@cumc.columbia.edu
Phone: 347-514-3366